Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

[1]  Abraham Schneider,et al.  Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Nelson,et al.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  C. Pashos,et al.  Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Goodwin,et al.  Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.

[5]  N. Parr,et al.  Testosterone recovery and changes in bone mineral density after stopping long‐term luteinizing hormone‐releasing hormone analogue therapy in osteoporotic patients with prostate cancer , 2005, BJU international.

[6]  J. Goodwin,et al.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The New England journal of medicine.

[7]  E. Strauss,et al.  Osteoporosis: a disease in men. , 2004, Clinical orthopaedics and related research.

[8]  C. Pashos,et al.  Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy , 2004, Cancer.

[9]  C. Higano.  Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. , 2004, The Urologic clinics of North America.

[10]  C. Higano,et al.  Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy , 2004, Cancer.

[11]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[12]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[13]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[14]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[15]  P. Kantoff,et al.  Low bone mineral density in hormone‐naïve men with prostate carcinoma , 2001, Cancer.

[16]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[17]  R. Parker,et al.  Early Changes in Biochemical Markers of Bone Turnover Predict the Long‐Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  D. Thiebaud,et al.  Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. , 1997, The American journal of medicine.

[19]  R. A. Jones,et al.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997, British journal of urology.

[20]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[21]  P. Diggle.  Analysis of Longitudinal Data , 1995 .

[22]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[23]  M. Duh,et al.  Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. , 2006, The Journal of urology.

[24]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density , 2003 .

[25]  M. Terris,et al.  Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. , 2001, Urology.

[26]  D. Ferguson,et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.